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Trial registrations

1. Introduction {#jia225048-sec-0005}
===============

In recent years, the debate regarding "treatment versus prevention" for HIV infection has shifted with adoption of the concept of "treatment‐as‐prevention" (TasP). Together with other compelling evidence from observational, ecological and modelling studies [1](#jia225048-bib-0001){ref-type="ref"}, [2](#jia225048-bib-0002){ref-type="ref"}, [3](#jia225048-bib-0003){ref-type="ref"}, [4](#jia225048-bib-0004){ref-type="ref"}, [5](#jia225048-bib-0005){ref-type="ref"}, the landmark HIV Prevention Trial Network (HPTN) 052 trial showcased TasP as a promising means to curb the global HIV epidemic. Indeed, the use of antiretroviral therapy (ART) was shown to be associated with a 93% reduction in HIV sexual transmission in HIV serodiscordant stable couples in whom the HIV‐positive partner was randomized to immediate initiation of ART irrespective of his/her individual clinical needs [6](#jia225048-bib-0006){ref-type="ref"}. Since then, the scientific rationale for TasP has expanded. In 2015, two randomized clinical trials showed that initiating ART as soon as possible after HIV diagnosis (regardless of disease stage) also yielded strong clinical benefits to the individual [7](#jia225048-bib-0007){ref-type="ref"}, [8](#jia225048-bib-0008){ref-type="ref"}.

The concept of TasP has been replaced by that of universal HIV testing and treatment (UTT), which offers HIV counselling and testing to an entire population and ART to all those HIV‐infected [9](#jia225048-bib-0009){ref-type="ref"}. In 2015, the World Health Organization (WHO) recommended that ART should be offered to all individuals diagnosed with HIV regardless of their CD4 count and clinical staging [10](#jia225048-bib-0010){ref-type="ref"}, and the Joint United Nations programme on HIV/AIDS (UNAIDS) proposed their 90‐90‐90 targets for HIV treatment scale‐up by 2020 (namely, that 90% of HIV‐infected persons know their status; that 90% of those who know their positive HIV status continue on an efficacious ART regimen; and that 90% of those on ART have undetectable HIV‐1 RNA) [11](#jia225048-bib-0011){ref-type="ref"}. Thus, the remaining research questions are "What are the feasibility, effects and costs of UTT on a population level, and how do we best implement this strategy?" Maximizing the coverage of HIV testing, effective linkage and retention in care, rapid access to and initiation of ART, and strong adherence for viral suppression are required to achieve the full potential impact of UTT [12](#jia225048-bib-0012){ref-type="ref"}, [13](#jia225048-bib-0013){ref-type="ref"}, [14](#jia225048-bib-0014){ref-type="ref"}, both on individual health outcomes for people living with HIV and on HIV incidence reduction.

Mathematical models have sought to predict the long‐term population‐level impact of UTT strategies on the epidemic [15](#jia225048-bib-0015){ref-type="ref"}, [16](#jia225048-bib-0016){ref-type="ref"}. All models have indicated that UTT could reduce HIV‐transmission, but the estimated impact of the UTT strategy on the reduction of HIV incidence ranged from 35% to 54% in the short‐term and from 32% to 74% in the longer term [16](#jia225048-bib-0016){ref-type="ref"}. Furthermore, these models vary greatly in structure and in parametric assumptions and rely on context‐specific variables, such as eligibility criteria for ART initiation, uptake and coverage of HIV testing, linkage to care, treatment initiation and adherence [13](#jia225048-bib-0013){ref-type="ref"}. Modelling the potential impact of UTT offered necessary but insufficient data points for national policy makers trying to determine how to successfully take UTT to scale in their unique contexts. As noted by the HIV Modelling Consortium, modelling is used to investigate the *potentia*l impact of UTT; empirical evidence from large randomized trials is needed to further assess the feasibility of rolling out UTT to whole communities [17](#jia225048-bib-0017){ref-type="ref"}.

As such, in a context where HIV funding is flat, obtaining evidence‐based data on UTT long‐term impact, cost‐effectiveness, feasibility, sustainability and acceptability at local and national levels is critical [15](#jia225048-bib-0015){ref-type="ref"}, [18](#jia225048-bib-0018){ref-type="ref"}. To fulfil this need, five community‐based trials were designed and implemented in the past five years in Southern and Eastern Africa. They were initiated before the WHO issued its recommendation for universal treatment [19](#jia225048-bib-0019){ref-type="ref"}, i.e. in a period of more restricted ART use [20](#jia225048-bib-0020){ref-type="ref"}. The common aim of these trials was to evaluate the effectiveness of UTT on HIV control in some of the most affected populations in sub‐Saharan Africa [21](#jia225048-bib-0021){ref-type="ref"}, [22](#jia225048-bib-0022){ref-type="ref"}, [23](#jia225048-bib-0023){ref-type="ref"}, [24](#jia225048-bib-0024){ref-type="ref"}, [25](#jia225048-bib-0025){ref-type="ref"}. In addition to measuring effects of UTT on HIV incidence, the studies are expected to provide critical data on the feasibility and cost of implementation of UTT (as well as more vs. less successful approaches to implementation), and thus to guide future policy and practice, by providing evidence for optimal scale‐up approaches [12](#jia225048-bib-0012){ref-type="ref"}.

Although the data collection of four out of five trials is not completed yet, the ongoing UTT trials have accumulated practical experience and data which could prove vital to large‐scale rollout of UTT strategies. The investigators of the five ongoing UTT randomized population‐based studies have agreed to collaborate as the Universal Test and Treat Trials Consortium (UT^3^C). This group shares protocols, field experiences and early data, to generate consensus statements when appropriate, and ultimately to facilitate joint analyses that can inform public policy and resource allocation.

The aim of this first paper is to describe, compare and contrast the contexts, research designs, intervention packages, themes explored and adaptations, that characterize these five ongoing large‐scale studies on UTT in Southern and Eastern Africa. This comparison will facilitate a better understanding of the results of these studies, when they are available, and may assist in understanding any differences found.

2. Methods {#jia225048-sec-0006}
==========

2.1. Design {#jia225048-sec-0007}
-----------

We conducted a comparative assessment of the five large‐scale UTT randomized studies conducted in sub‐Saharan Africa: the ANRS 12,249 TasP (ANRS TasP) trial in South Africa [21](#jia225048-bib-0021){ref-type="ref"}, the *Max*ART study in Swaziland [22](#jia225048-bib-0022){ref-type="ref"}, the HPTN 071 (PopART) trial in South Africa and Zambia [23](#jia225048-bib-0023){ref-type="ref"}, the SEARCH trial in Uganda and Kenya [24](#jia225048-bib-0024){ref-type="ref"} and the BCPP/YaTsie (BCPP) trial in Botswana [25](#jia225048-bib-0025){ref-type="ref"}. UTT trials gathered as a consortium (UT^3^C) constituted of two to three representatives per trial, including a trial principal investigator. After sharing trial protocols, we screened for essential study characteristics and consensually decided which should be compared and at what level of detail. Then we highlighted and interpreted differences and commonalities across the trials. Over a year and a half period, information was exchanged via emails (twice monthly), teleconferences (once monthly) and a half‐day meeting held prior to the manuscript submission. The first and last authors of the present manuscript led this collaborative work.

2.2. Sources of information {#jia225048-sec-0008}
---------------------------

We first extracted information from the trial protocols: BCPP V4.0 (7 December 2015 for Evaluation Protocol, and 15 April 2016 for Intervention Protocol) [26](#jia225048-bib-0026){ref-type="ref"}, *Max*ART V2.0 (7 September 2015) [22](#jia225048-bib-0022){ref-type="ref"}, PopART V3.0 (16 November 2015) [23](#jia225048-bib-0023){ref-type="ref"}, SEARCH V7.0 (5 February 2016) [27](#jia225048-bib-0027){ref-type="ref"}, ANRS TasP V3.0 (12 March 2015) [21](#jia225048-bib-0021){ref-type="ref"}. We also extracted data from amendments to the trial protocols and sought input (including confirmation of accuracy) from study investigators where necessary. Finally, we included data from the study baseline and from national surveys (e.g. national HIV prevalence surveys, national Demographic and Health surveys, national Population and Housing censuses, national Poverty surveys, national Labour surveys, national UNAIDS global AIDS response reports, statistics of the United Nations Educational, Scientific and Cultural Organization, WHO country statistical profiles, World Bank reports).

2.3. Analysis {#jia225048-sec-0009}
-------------

We identified study characteristics that were deemed essential for comparing the UTT trials and organized them in five categories: (1) Trial contexts: key demographic and socio‐economic characteristics of the populations living in the trial areas, health services available in the trial areas, and their HIV epidemiological profiles; (2) Trial research methodologies: trial design, primary outcome, populations and other methodological considerations; (3) Trial intervention packages: services delivered in the trial intervention and control arms as well as national standard of care; (4) Trial themes: areas of interest of the trials and data collected for secondary outcomes; (5) Trial adaptations: modifications of the trial designs and interventions during the conduct of the trials, especially in response to evolving treatment guidelines. The identification of those five categories as well as the interpretation of the results was done collectively, until a consensus was reached within the cross‐study collaboration.

3. Results {#jia225048-sec-0010}
==========

3.1. Trial contexts {#jia225048-sec-0011}
-------------------

Table [1](#jia225048-tbl-0001){ref-type="table-wrap"} characterizes the trial population and their contexts at baseline (See Table [S1](#jia225048-sup-0001){ref-type="supplementary-material"} for national indicators). The trials vary in terms of the demographic composition. For example in SEARCH, half of the population living in the trial area is less than 15 years old (unpublished trial data), whereas in the South African study sites of PopART,26% of people are aged ≤15 years old (unpublished trial data). The trial contexts also differ in the economies involved (e.g. unemployment, poverty) as well as the education level of their populations. The proportion of adults who had no secondary school education ranged from 13% in the South African communities of PopART (unpublished data) to 71% in the SEARCH communities [28](#jia225048-bib-0028){ref-type="ref"}. While all trials are conducted in areas which suffer from generalized HIV epidemics, the baseline prevalence of HIV also varied and was estimated to be 30% TasP trial sites [29](#jia225048-bib-0029){ref-type="ref"}, 29% in BCPP [30](#jia225048-bib-0030){ref-type="ref"}, 29% in *Max*ART [31](#jia225048-bib-0031){ref-type="ref"}, 22% in the South African sites of the PopART (unpublished data), 21% in the Zambian sites of PopART (unpublished data), 20% in SEARCH Kenyan communities [32](#jia225048-bib-0032){ref-type="ref"}, and is less than 10% in the SEARCH Ugandan communities [32](#jia225048-bib-0032){ref-type="ref"}. Finally, important disparities are observed across trials in relation to the extent of development of the HIV health systems at baseline. The *Max*ART and BCPP trials are being implemented in areas characterized by a relatively high ART coverage with, respectively, 85% [33](#jia225048-bib-0033){ref-type="ref"} and 73% [30](#jia225048-bib-0030){ref-type="ref"} of the adult population over 15 years old on ART. In SEARCH, an estimated 57% of people ≥15 years old are on ART at baseline [32](#jia225048-bib-0032){ref-type="ref"}. TasP and PopART trials accounted for the smallest ART coverages with less than half of the population on ART in their study sites (38% among \>15 years old in TasP [34](#jia225048-bib-0034){ref-type="ref"}, 30% and 39% among 18 to 44 years old in the South African and Zambian PopART communities (unpublished work)). Despite significant progress of the local governments in fighting the epidemics through a series of strategic and operational plans, the overall health sector response and capacity have not yet met the needs of the local population in all these settings. The epidemics continue to spread along socio‐economic development fault lines such as poverty, gender inequality, unemployment and lack of adequate social protection among others [35](#jia225048-bib-0035){ref-type="ref"}.

###### 

Trial background characteristics at baseline

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial indicators                                                                          BCPP                                                                                                                                                                                                                                                                                                                                           *Max*ART                                                                                                            PopART                                                                                                                                                                                                  SEARCH                                                                                                                                                                                                                                                                                                                               ANRS TasP
  ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Census and demographic                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  Residency                                                                                 Rural and peri‐urban                                                                                                                                                                                                                                                                                                                           Peri‐urban and rural                                                                                                Peri‐urban                                                                                                                                                                                              Rural                                                                                                                                                                                                                                                                                                                                Rural

  Young in population living in trial area (%)[b](#jia225048-note-0003){ref-type="fn"}      42% aged \<16 or \>64 years old[b](#jia225048-note-0003){ref-type="fn"} [36](#jia225048-bib-0036){ref-type="ref"}                                                                                                                                                                                                                              38% aged \<15 years old[c](#jia225048-note-0004){ref-type="fn"} (2013) [37](#jia225048-bib-0037){ref-type="ref"}    SA: 26% aged ≤15 years old[b](#jia225048-note-0003){ref-type="fn"}\                                                                                                                                     50% aged \<15 years old[b](#jia225048-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                      30% aged \<15 years old[c](#jia225048-note-0004){ref-type="fn"} (2013) [38](#jia225048-bib-0038){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 40% aged ≤15 years old[b](#jia225048-note-0003){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Median age of research study population (years)[a](#jia225048-note-0002){ref-type="fn"}   40 years old \[IQR: 33 to 48\][a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                         33 years old \[IQR: 24 to 45\][a](#jia225048-note-0002){ref-type="fn"}                                              27 years old \[IQR: 22 to 33\][a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                  29 years old \[IQR: 20 to 43\][a](#jia225048-note-0002){ref-type="fn"} [28](#jia225048-bib-0028){ref-type="ref"}                                                                                                                                                                                                                     32 years old \[IQR: 22 to 52\][a](#jia225048-note-0002){ref-type="fn"} [34](#jia225048-bib-0034){ref-type="ref"}

  Female in research study population (%)[a](#jia225048-note-0002){ref-type="fn"}           64%[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                    64%[a](#jia225048-note-0002){ref-type="fn"}                                                                         SA: 69%[a](#jia225048-note-0002){ref-type="fn"}\                                                                                                                                                        53%[a](#jia225048-note-0002){ref-type="fn"} [28](#jia225048-bib-0028){ref-type="ref"}                                                                                                                                                                                                                                                70%[a](#jia225048-note-0002){ref-type="fn"} [29](#jia225048-bib-0029){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 72%[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Labour and poverty                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Unemployed working‐age population (%)                                                     59%[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                    42%[c](#jia225048-note-0004){ref-type="fn"} (2013) [39](#jia225048-bib-0039){ref-type="ref"}                        SA: 72%[a](#jia225048-note-0002){ref-type="fn"}\                                                                                                                                                        5%[a](#jia225048-note-0002){ref-type="fn"} [28](#jia225048-bib-0028){ref-type="ref"}                                                                                                                                                                                                                                                 90%[a](#jia225048-note-0002){ref-type="fn"} [34](#jia225048-bib-0034){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 77%[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Population living under the national poverty lines (%)                                    15%[c](#jia225048-note-0004){ref-type="fn"} (2010) [40](#jia225048-bib-0040){ref-type="ref"}                                                                                                                                                                                                                                                   63%[c](#jia225048-note-0004){ref-type="fn"} (2009) [41](#jia225048-bib-0041){ref-type="ref"}                        SA: 54%[c](#jia225048-note-0004){ref-type="fn"} (2010) [42](#jia225048-bib-0042){ref-type="ref"}\                                                                                                       U: 19%[c](#jia225048-note-0004){ref-type="fn"} (2012) [44](#jia225048-bib-0044){ref-type="ref"}\                                                                                                                                                                                                                                     54% (2010)[c](#jia225048-note-0004){ref-type="fn"} [42](#jia225048-bib-0042){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 46%[c](#jia225048-note-0004){ref-type="fn"} (2010) [43](#jia225048-bib-0043){ref-type="ref"}                                                                                                         K: 46%[c](#jia225048-note-0004){ref-type="fn"} (2005) [45](#jia225048-bib-0045){ref-type="ref"}                                                                                                                                                                                                                                      

  Education and health                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Adult population with primary education or less (%)                                       31%[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                    31%[a](#jia225048-note-0002){ref-type="fn"}                                                                         SA: 13%[a](#jia225048-note-0002){ref-type="fn"}\                                                                                                                                                        71%[a](#jia225048-note-0002){ref-type="fn"} [28](#jia225048-bib-0028){ref-type="ref"}                                                                                                                                                                                                                                                41%[a](#jia225048-note-0002){ref-type="fn"} [34](#jia225048-bib-0034){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 35%[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  HIV prevalence (%)                                                                        29% among 16 to 64 years old[a](#jia225048-note-0002){ref-type="fn"} (2013) [30](#jia225048-bib-0030){ref-type="ref"}                                                                                                                                                                                                                          29% among \>15 years old[c](#jia225048-note-0004){ref-type="fn"} (2015) [31](#jia225048-bib-0031){ref-type="ref"}   SA: 22% among 18 to 44 years old[a](#jia225048-note-0002){ref-type="fn"} (2014)\                                                                                                                        SW‐U: 7% among ≥15 years old[a](#jia225048-note-0002){ref-type="fn"} (2013) [32](#jia225048-bib-0032){ref-type="ref"}\                                                                                                                                                                                                               30% among \>15 years old[a](#jia225048-note-0002){ref-type="fn"} (2012) [29](#jia225048-bib-0029){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 21% among 18 to 44 years old[a](#jia225048-note-0002){ref-type="fn"} (2014)                                                                                                                          E‐U: 3% among ≥15 years old[a](#jia225048-note-0002){ref-type="fn"} (2013) [32](#jia225048-bib-0032){ref-type="ref"}\                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       K: 20% among ≥15 years old[a](#jia225048-note-0002){ref-type="fn"} (2013) [32](#jia225048-bib-0032){ref-type="ref"}                                                                                                                                                                                                                  

  HIV+ population on ART (%)                                                                73% among \>15 years old[a](#jia225048-note-0002){ref-type="fn"} [30](#jia225048-bib-0030){ref-type="ref"}                                                                                                                                                                                                                                     85% among \>15 years old[c](#jia225048-note-0004){ref-type="fn"} (2013) [33](#jia225048-bib-0033){ref-type="ref"}   SA: 30% among 18 to 44 years old[a](#jia225048-note-0002){ref-type="fn"}\                                                                                                                               57% among ≥15 years old[a](#jia225048-note-0002){ref-type="fn"} [32](#jia225048-bib-0032){ref-type="ref"}                                                                                                                                                                                                                            38% among \>15 years old[a](#jia225048-note-0002){ref-type="fn"} [34](#jia225048-bib-0034){ref-type="ref"}
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 39% among 18 to 44 years old[a](#jia225048-note-0002){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Status of UNAIDS 90/90/90 targets[d](#jia225048-note-0005){ref-type="fn"}                 83% of the HIV+ aged 16 to 64 years in the study population knew their status; of those 87% were taking ART; of those, 96.5% were virally suppressed (HIV RNA\<400 copies/ml). The estimated population‐level viral suppression among HIV+ adults was 70%[a](#jia225048-note-0002){ref-type="fn"} [30](#jia225048-bib-0030){ref-type="ref"}.   Estimates are unavailable at this time                                                                              SA: Estimates are unavailable at this time\                                                                                                                                                             68% of the HIV+ in the study population knew their status; of those 80% had received ART; of those, 86% were virally suppressed (HIV RNA\<500 copies/ml). The estimated population‐level viral suppression among HIV+ adults was 47% at baseline[a](#jia225048-note-0002){ref-type="fn"} [32](#jia225048-bib-0032){ref-type="ref"}   At the beginning of the trial, 85.8% were estimated to be diagnosed; of those, 37.1% to be engaged in care and actively on ART; on those 77.8% with a documented viral load and virally suppressed [47](#jia225048-bib-0047){ref-type="ref"}. Note that trial start corresponds to different time points as all clusters were not opened at same time.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Z: 54% of the HIV+ aged ≥18 years old in the study population knew their HIV+ status; of those 81% were taking ART[a](#jia225048-note-0002){ref-type="fn"} [46](#jia225048-bib-0046){ref-type="ref"}.                                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Denotes the research study population, which is the population in which the primary outcome and main secondary outcomes (among adults) are being measured. (The eligibility criteria for the research study population are specified in Table [3](#jia225048-tbl-0003){ref-type="table-wrap"}). Data were collected at baseline by the trial team and extracted from publications and conference abstracts.

Denotes the population living in the trial area; data collected at baseline by the trial team.

Denotes the populations of the countries in which the trials have been implemented; data from national surveys. IQR: Interquartile range; SA: South Africa; Z: Zambia; K: Kenya; U: Uganda; SW‐U: Southwestern Uganda; E‐U: Eastern Uganda.

Quantitative comparison of the estimates 90‐90‐90 UNAIDS targets at baseline should be performed cautiously, as there is no standard methodology across trials to compute these figures and is the focus of a separate cross‐trial collaboration.

John Wiley & Sons, Ltd

3.2. Trial research designs {#jia225048-sec-0012}
---------------------------

As presented in Table [2](#jia225048-tbl-0002){ref-type="table-wrap"}, the five UTT trials share a common primary aim, which is to assess the impact of UTT on the HIV epidemic. Each trial compares outcomes between communities where all HIV‐infected persons are offered ART regardless of immunological status or clinical stage (among other interventions) and communities where HIV‐infected persons receive ART according to the national guidelines. All trials examine the long‐term benefits and sustainability of the UTT intervention with their extended observation periods (≥3 years). With this common framework, the trials differ somewhat in their designs, with four adopting a community‐randomized design and one adopting a stepped‐wedge clinic‐randomized design. The trials also differ in the number of study arms, with four trials designed with two arms and one trial with three arms.

###### 

Trial research methodologies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial       Countries              Design                                                                  Primary objective                                                                                                                                                                                                                                                                                                                                       Primary outcome                   Study power                                                                                                                                            Coefficient of variation between clusters   Estimated trial impact                                                                                                                Duration (average follow‐up)[a](#jia225048-note-0007){ref-type="fn"}   Estimated completion date
  ----------- ---------------------- ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ---------------------------
  BCPP        Botswana               2 arm community‐level pair‐matched cluster‐randomized trial             To evaluate whether expanded ART initiation (initially by high HIV‐1 RNA level and higher CD4 threshold, now universal ART), combined with strengthened and expanded HIV testing/linkage and male circumcision services, can significantly reduce cumulative HIV incidence at population‐level, in 16 to 64 year old community residents in Botswana.   Cumulative HIV incidence          86% (original parameters and ART initiation criteria)\                                                                                                 0.26                                        40% reduction of cumulative HIV incidence in the intervention arm                                                                     60 months\                                                             October 2018
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       72% (revised parameters based on observed data, and actual ART initiation criteria over time)                                                                                                                                                                                                                                            (average follow‐up of 36 months)                                       

  *Max*ART    Swaziland              2 arm clinic‐catchment level ‐ stepped‐wedge cluster‐randomized trial   To evaluate whether early ART initiation for all HIV+ individuals can improve retention and viral suppression at population‐level, in over 18‐year‐olds, in Swaziland\'s government‐managed health system.                                                                                                                                              Retention and viral suppression   80%                                                                                                                                                    0.5                                         6% increase in 1‐year retention rate between the control phase and intervention phase                                                 36 months                                                              August 2017

  PopART      South Africa, Zambia   3 arm community‐level triplet‐matched cluster‐randomized trial          To determine the impact of two community‐level combination prevention packages, both of which include universal HIV testing and intensified provision of HIV ART and care, on population‐level HIV incidence                                                                                                                                            Cumulative HIV incidence          \>99% for Arm A versus Arm C comparison (original model parameters and ART initiation criteria);\                                                      0.15 to 0.2                                 60% to 65% reduction in HIV incidence in arm A in years 2 and 3 of intervention (original parameters and ART initiation criteria);\   54 months\                                                             June 2018
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       In range 44% to 95% for Arm A versus Arm C comparison (revised parameters based on trial data including on testing and treatment coverage over time)                                               35% to 45% reduction of HIV incidence in arm A in years 2 and 3 of intervention (revised parameters)                                  (average follow‐up of 36 months)                                       

  SEARCH      Uganda, Kenya          2 arm 2 phase community‐level pair‐matched cluster‐randomized trial     Phase 1: To quantify the impact of early HIV diagnosis and immediate ART using a streamlined care delivery system on the three‐year cumulative HIV incidence among adults aged ≥15 years old in rural communities in Uganda and Kenya\                                                                                                                  Cumulative HIV incidence          80% in both Phase1 and Phase2                                                                                                                          ≤0.4                                        40% reduction in cumulative HIV incidence (both Phase 1 and 2) in the intervention arm                                                72 months\                                                             June 2017 for Phase1\
                                                                                                             Phase 2: To quantify the impact of targeted PrEP, targeted HIV testing and targeted care interventions on top of universal treatment and streamlined care on the 3‐year cumulative HIV incidence among adults aged ≥15 years old in rural communities in Uganda and Kenya                                                                                                                                                                                                                                                                                                                                                                                                                                                          (follow‐up of 36 months in Phase 1 and 36 months in Phase 2)           June 2020 for Phase2

  ANRS TasP   South Africa           2 arm community‐level cluster‐randomized trial                          Phase 1: To estimate the feasibility and acceptability of early ART initiation for all HIV+ individuals combined with six monthly home‐based HIV testing of all adult members of a community and linkage‐to‐care services at population‐level in 16 and above years of age, in KwaZulu‐Natal province in South Africa.\                                 Cumulative HIV incidence          80%                                                                                                                                                    0.25                                        A 34% reduction in cumulative HIV incidence in the intervention arm                                                                   52 months\                                                             June 2014 for Phase 1\
                                                                                                             Phase 2: To compare how early ART initiation for all HIV+ individuals combined with six monthly home‐based HIV testing of all adult members of a community and linkage‐to‐care services can impact on the reduction in incidence of new HIV infections at population‐level in 16 and above years of age, in KwaZulu‐Natal province in South Africa.                                                                                                                                                                                                                                                                                                                                                                                (average follow‐up of 36 months)                                       July 2016 for Phase 2
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ART, antiretroviral therapy; PrEP, pre‐exposure prophylaxis.

The trial duration refers to the period between the first day an intervention was provided to a study participant and the last day an intervention was provided to a study participant. The average follow‐up refers to the average time a study participant was observed in the context of the trial.

John Wiley & Sons, Ltd

With study‐specific definitions of residency, Table [3](#jia225048-tbl-0003){ref-type="table-wrap"} shows that the selection of the trial clusters (i.e. communities or clinic‐catchment areas) were based on diverse criteria. All trials made efforts for their clusters to be large (to ensure that most sexual contacts occur within the cluster) and dispersed (to minimize contamination and overlapping catchment of different health facilities). Two out of the five trials are implementing a pair‐matched design, and one trial is triplet‐matched. With study‐specific definitions of residency, the trial population and eligibility criteria and sizes varied greatly between studies. All trials carefully defined the population that was eligible for the trial interventions (intervention population) which ranged from 4000 to a million of individuals. They collect specific information on selected samples (research study population) and measure the primary outcome through more intensive observations (evaluation population). The study settings are all characterized by some degrees of mobility in and out of the study communities. (Migration rates and characteristics of migrants will be reported in trial‐specific publications.)

###### 

Trial population characteristics at baseline

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                              BCPP                                                                                                                                       *Max*ART                                                                               PopART                                                                                                                               SEARCH                                                                                                                                                                                                                                  ANRS TasP
  ------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  Cluster selection criteria                                                                  Located in one of three populated geographical regions of Botswana\                                                                        Located in the Hhohho region in Swaziland\                                             Located in Western cape province of South Africa or Zambia\                                                                          Located in Southwestern, Eastern Uganda or Western Kenya\                                                                                                                                                                               Located in the Hlabisa sub‐district in KwaZulu‐Natal province, South Africa\
                                                                                              Geographically distinct communities, reachable by road\                                                                                    Catchment area of a government primary health care facility which provides HIV care\   Non‐adjacent communities\                                                                                                            Non‐adjacent communities\                                                                                                                                                                                                               Neighbouring communities with clear geographical boundaries and distinct social identities\
                                                                                              Containing a government primary health care facility (clinic or hospital) which provides ART and PMTCT\                                    Not a site for another research activity that could impact the trial outcomes          Catchment area of a government primary health care facility which provides HIV and TB care\                                          Served by a government primary health care facility which provides HIV care\                                                                                                                                                            ≥15 km^2^\
                                                                                              Community size 2500 to 15,000 (ideal 6000)\                                                                                                                                                                                       Population ≥20,000\                                                                                                                  Accessibility to health centre via maintained transportation route\                                                                                                                                                                     Not site for other research activities that could impact the trial outcomes
                                                                                              Not site for other research activities that could impact the trial outcomes                                                                                                                                                       High HIV prevalence\                                                                                                                 Between 9000 and 11,0000 individuals, not in an urban setting i.e. ≤100,000\                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                Not site for other research activities that could impact the trial outcomes                                                          Not site for other research activities that could impact the trial outcomes                                                                                                                                                             

  Cluster matching and/or stratified randomization and/or restricted randomization criteria   Matching: geographical location, community size, population age structure, baseline access to health services including ART\               Matching: geographical location, clinic‐catchment size\                                Matching: geographical location, HIV prevalence\                                                                                     Matching: geographical location (Phase1 and 2), population density (Phase1), migration (Phase1), occupation (Phase1), number of trading centres (Phase1), Phase 1 intervention arm (Phase2), other drivers of HIV incidence (Phase2)\   No matching\
                                                                                              Randomized within matched pairs                                                                                                            Stratified randomization                                                               Restricted randomization: Community size, ART uptake, HIV prevalence                                                                 Randomized within matched pairs                                                                                                                                                                                                         Stratified randomization: HIV prevalence

  Number of clusters                                                                          30                                                                                                                                         14                                                                                     21\                                                                                                                                  32\                                                                                                                                                                                                                                     22
                                                                                                                                                                                                                                                                                                                                (12 in Zambia\                                                                                                                       (10 in Southwestern Uganda, 10 in Eastern Uganda and 12 in Kenya)                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                and 9 in South Africa)                                                                                                                                                                                                                                                                                                                                                       

  Average cluster population size \[range\][a](#jia225048-note-0009){ref-type="fn"}           5785 \[2748 to 12,865\]                                                                                                                    8553 \[5326 to 14,868\]                                                                44,000 \[\~16,000‐\~100,000\]                                                                                                        10,450 \[8401 -- 12,990\]                                                                                                                                                                                                               1284 \[324 to 2861\] (for those aged ≥16 years old)

  Intervention population size[b](#jia225048-note-0010){ref-type="fn"}                        105,000 (age 16 to 64 years)                                                                                                               4501                                                                                   \~1000,000                                                                                                                           334,512                                                                                                                                                                                                                                 28,260

  Intervention population eligibility criteria[b](#jia225048-note-0010){ref-type="fn"}        Gave verbal informed consent\                                                                                                              Gave verbal informed consent\                                                          Gave verbal informed consent\                                                                                                        Gave verbal informed consent\                                                                                                                                                                                                           Gave a written informed consent\
                                                                                              Is aged ≥16 years\                                                                                                                         Is aged ≥18 years\                                                                     Is aged ≥18 years (Year 1, first months of Year 2); all ages (1 October 2015 onwards)                                                Is a member of a study household in the trial area                                                                                                                                                                                      Is aged ≥16 years\
                                                                                              Is present at least three nights per month on average in the community over the prior 12 months[a](#jia225048-note-0009){ref-type="fn"}\   Is attending one of the study facilities\                                                                                                                                                                                                                                                                                                                                                                                                                           Is a member of a study household in the trial area
                                                                                              Is a Botswana citizen (or spouse of citizen)[e](#jia225048-note-0013){ref-type="fn"}                                                       Is not pregnant or breastfeeding at time of enrolment\                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                                         Is HIV‐positive and ART naïve                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Research study population size[c](#jia225048-note-0011){ref-type="fn"}                      22,000                                                                                                                                     4501                                                                                   43,601                                                                                                                               146,906                                                                                                                                                                                                                                 28,260

  Research study population eligibility criteria[c](#jia225048-note-0011){ref-type="fn"}      Gave written informed consent (or parental permission and child assent if \<18 years old)\                                                 Gave written informed consent\                                                         Gave written informed consent\                                                                                                       Gave verbal informed consent\                                                                                                                                                                                                           Is a member of the intervention population
                                                                                              Is aged 16 to 64 years\                                                                                                                    Is a participant to the intervention population                                        Is a member of the trial population\                                                                                                 Is a member of the intervention population\                                                                                                                                                                                             
                                                                                              Is present at least three nights per month on average in the community over the prior 12 months\                                                                                                                                  Is aged ≥18 and ≤44 years\                                                                                                           Is aged ≥15 years at baseline\                                                                                                                                                                                                          
                                                                                              Is a Botswana citizen (or spouse of citizen)\                                                                                                                                                                                     Is present in one of the 2500 study households randomly selected in each cluster; and intending to remain so for the next 3 years\   Is present in a study community for ≥6 months of the year prior the study start                                                                                                                                                         
                                                                                              Is present in one of the 20% randomly selected study households\                                                                                                                                                                  Is not currently enrolled in another ART or PreP study\                                                                                                                                                                                                                                                                                                                      
                                                                                              Is not currently incarcerated                                                                                                                                                                                                     Has not been or is not currently enrolled in an HIV vaccine study                                                                                                                                                                                                                                                                                                            

  Evaluation population size[d](#jia225048-note-0012){ref-type="fn"}                          9000                                                                                                                                       4501                                                                                   \~33,000                                                                                                                             118,038                                                                                                                                                                                                                                 17,659

  Evaluation population eligibility criteria[d](#jia225048-note-0012){ref-type="fn"}          Is a member of the research study population\                                                                                              Is a member of the research study population                                           Is a member of the research study population\                                                                                        Is a member of the research study population\                                                                                                                                                                                           Is a participant to the research study population\
                                                                                              Is HIV‐negative at baseline                                                                                                                                                                                                       Is HIV‐negative                                                                                                                      Is HIV‐negative at baseline                                                                                                                                                                                                             Is HIV‐negative at baseline
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PMTCT, prevention of mother‐to‐child transmission; ART, antiretroviral therapy; PrEP, pre‐exposure prophylaxis.

Cluster population: Total population of a trial cluster (estimated with baseline data).

Intervention Population: Population that is eligible for trial interventions, which for purposes of this definition are testing services in the ANRS TasP, BCPP, PopART and SEARCH trials, or HIV treatment services in the *Max*ART trial (estimated with baseline trial data).

Research study population: Population in which the primary outcome and main secondary outcomes (among adults) are being measured (estimated with baseline data).

Evaluation population: Population in which the trial impact is being evaluated i.e. in which the primary outcome is being measured (estimated with baseline data).

In the BCPP trial, being a Botswana citizen (or spouse of a Botswana citizen) and being present at least three nights per month on average in the community over the prior 12 months are eligibility criteria to access early ART but not to access HIV testing and counselling).

John Wiley & Sons, Ltd

3.3. Trial intervention packages {#jia225048-sec-0013}
--------------------------------

As displayed in Table [4](#jia225048-tbl-0004){ref-type="table-wrap"}, the administration of universal ART is randomized at the community or clinic‐level in all trials. Participants in the intervention arms are offered ART initiation regardless of immunological status or clinical stage. Initially BCPP participants were offered ART if CD4 count ≥350 cells/μl and HIV‐1 RNA ≥10,000 copies/ml, or if CD4 count \<350 cells/μl regardless of HIV‐1 RNA. However, with emerging data and evolving WHO recommendations, all HIV‐infected participants are now offered ART. In the control arms of all trials, ART initiation follows national guidelines. In the intervention arms of some trials, additional services are provided, enhanced and/or delivered according to the principles of differentiated care [48](#jia225048-bib-0048){ref-type="ref"}, [49](#jia225048-bib-0049){ref-type="ref"}, [50](#jia225048-bib-0050){ref-type="ref"}, [51](#jia225048-bib-0051){ref-type="ref"}: activities to engage the community in accessing HIV care (e.g. roadshows), intensive HIV voluntary testing options (e.g. mobile testing, home‐based testing), intensified health prevention services (e.g. voluntary medical male circumcision (VMMC), screening for HIV‐related diseases and non‐communicable diseases), and support activities for linking and staying in care (e.g. counselling, short message service clinic appointment reminders, follow‐up phone calls). These intervention packages emphasize the key role of an early ART initiation in a wider combination prevention strategy. Furthermore, only a small proportion of those activities is offered in the national standard of care (or offered on a much smaller scale); thus the overall quality and in some cases, efficiency of care delivered to study participants is increased relative to the general population.

###### 

Trial interventions

                                                                                                                                 BCPP                                        *Max*ART                                    PopART   SEARCH   ANRS TasP                                                                                                                                                                                                                                                                                                                                         
  ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------- ------------------------------------------- -------- -------- ----------- ------ --- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------------------- ------ ------------------------------------------- ------------------------------------------- -------
  Community mobilization                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Specific mobile activities in the community (e.g. roadshows, public announcements from vehicles, door‐to‐door communication)   x[a](#jia225048-note-0015){ref-type="fn"}   x                                           N.A.     **x**    **x**       N.A.   x   x                                                                                       N.A.                                        x[a](#jia225048-note-0015){ref-type="fn"}   x                                           N.A.   x                                           x                                           N.A.
  Communication through existing community platforms (e.g. community meetings, civic society activities, schools, clinics)       x[a](#jia225048-note-0015){ref-type="fn"}   x                                           N.A.     **x**    **x**       N.A.   x   x                                           x                                           N.A.                                        x[a](#jia225048-note-0015){ref-type="fn"}   x                                           N.A.   x                                           x                                           N.A.
  Health prevention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Distribution of condoms                                                                                                        x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                             x      x   x                                           x                                           x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  Male circumcision                                                                                                              x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                             x      x   x                                           x                                           x                                                                                                                                   x                                                                                              x
  PrEP                                                                                                                                                                                                                                                                                                                                                                                                x[f](#jia225048-note-0020){ref-type="fn"}                                                                                                                                              
  PMTCT Option B+                                                                                                                x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                             x      x   x                                           x                                           x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  STI screening                                                                                                                  x                                           x                                           x                             x      x   x                                                                                       x                                                                                                                                   x      x                                           x                                           x
  STI treating                                                                                                                   x                                           x                                           x                             x                                                                                                  x                                                                                                                                   x                                                                                              x
  TB screening                                                                                                                   x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                             x      x   x                                                                                       x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  TB treating                                                                                                                    x                                           x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                                                                                              x
  Cervical cancer screening                                                                                                                                                                                              x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  Other HIV opportunistic infections screening                                                                                   x                                           x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  Screening for chronic illnesses (diabetes and/or hypertension)                                                                 x                                           x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  Child care (e.g. immunization, deworming)                                                                                      x                                           x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                                                                                              x
  Family planning                                                                                                                x                                           x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                                                                                              x
  Antenatal and postnatal care                                                                                                   x                                           x                                           x                             x                                                                                                  x                                                                                                                                   x                                                                                              x
  Others (e.g. malaria screening and/or treatment, urgent care, men\'s health services, dermatological services)                 x                                           x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                                                                                              **x**
  HIV testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  Voluntary HIV testing and counselling                                                                                          x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x        x        x           x      x   x                                                                                       x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                                                                       x
  Provider‐initiated HIV testing and counselling in health facilities                                                            x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                             x                                                                                                  x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x                                                                                              x
  Home‐based HIV testing                                                                                                         x[a](#jia225048-note-0015){ref-type="fn"}   x[b](#jia225048-note-0016){ref-type="fn"}                                        x   x                                                                                                                                   x[a](#jia225048-note-0015){ref-type="fn"}   x                                                  x                                           x                                           
  HIV testing in mobile units                                                                                                    x                                                                                                                                                                                                                                                                    x[a](#jia225048-note-0015){ref-type="fn"}   x                                                  x[f](#jia225048-note-0020){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}   
  HIV testing during mobile community campaigns                                                                                  x                                                                                                                            x   x                                                                                                                                   x[a](#jia225048-note-0015){ref-type="fn"}   x                                                                                                                                          
  HIV treatment[c](#jia225048-note-0017){ref-type="fn"}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  ART initiation of HIV+ individuals with CD4 count ≤500 cells/μl                                                                x                                           x                                           x                 x           x          x[d](#jia225048-note-0018){ref-type="fn"}   x[d](#jia225048-note-0018){ref-type="fn"}   x[d](#jia225048-note-0018){ref-type="fn"}                                               x[e](#jia225048-note-0019){ref-type="fn"}   x                                                  x                                           x
  ART initiation of all HIV+ individuals                                                                                         x                                           x                                           x        x                           x   x[d](#jia225048-note-0018){ref-type="fn"}   x[d](#jia225048-note-0018){ref-type="fn"}   x[d](#jia225048-note-0018){ref-type="fn"}   x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}          x                                                                                       
  Linkage to and retention in care                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Clinic referral upon HIV‐positive screen                                                                                       x                                           x                                           x                             x      x   x                                                                                       x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           x
  Linkage to care counselling phone calls                                                                                        x                                                                                                                                                                                                                                                                    x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}          x                                           x                                           
  SMS clinic appointment reminders                                                                                               x                                                                                                                                                                                                                                                                    x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}                                                                                                  
  Repeated home visits                                                                                                           x                                                                                                                            x   x                                                                                                                                   x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}          x                                           x                                           
  Rapid ART initiation (e.g. on the same day as HIV diagnosis)                                                                   x                                                                                                x                                                                                                                                                                   x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}                                                                                                  
  Adherence support (e.g. support group)                                                                                         x                                           x                                           x                                    x   x                                                                                                                                   x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}                                                                                                  
  Convenient ART refill process                                                                                                  x                                                                                                                                                                                                                                                                    x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}                                                                                                  
  Non‐cash incentive (e.g. phone airtime)                                                                                        x                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Transportation voucher                                                                                                         x                                           x                                                                                                                                                                                                                        x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}                                                                                                  
  Point‐of‐care CD4                                                                                                              x                                           x[b](#jia225048-note-0016){ref-type="fn"}            x        x                                                                                                                                                          x[a](#jia225048-note-0015){ref-type="fn"}   x                                           x      x                                           x                                           
  Viral load monitoring                                                                                                          x                                           x                                           x        x        x                                                                                                              x                                           x[a](#jia225048-note-0015){ref-type="fn"}   x[f](#jia225048-note-0020){ref-type="fn"}   x      x                                           x                                           x

This table displays information which is valid up to July 2016. S, Services that should be available in both intervention and control arms as the standard of care according to the national guidelines; C, Services delivered in the trial control arm; I: Services delivered in the intervention arm in all trials except PopART; A, Services delivered in the intervention arm A in PopART; B, Services delivered in the intervention arm B in PopART; N.A., Non applicable. PrEP, pre‐exposure prophylaxis; PMTCT, prevention of mother‐to‐child transmission; STI, sexually transmitted infections; SMS, short message service.

Enhanced provision of these services in the Intervention arm as compared to the Standard of care (S) and Control arms (C).

In the BCPP trial, the home‐based testing services including point‐of‐care CD4 are available to 20% of the study population in control communities, and 100% in intervention communities.

The details of treatment eligibility at different times are to be found in Figure [1](#jia225048-fig-0001){ref-type="fig"}.

In the PopART trial, the control arms B and C provide ART initiation of all in Zambia and ART initiation with CD4 count ≤500 cells/μl in South Africa.

Services delivered during the phase 1 of the SEARCH trial.

Services delivered during the phase 2 of the SEARCH trial.

John Wiley & Sons, Ltd

Health services are delivered through three main means. First, each trial community is serviced by clinics that provide most of the conventional health activities including HIV care and treatment. In BCPP, *Max*ART, PopART and SEARCH, the trial clinics are government‐led (with strengthening of government staff by some trials), whereas in TasP, the clinics are built for the purpose of the trial to bring services closer to people\'s homes. Second, health services are also delivered through community‐based activities like home visits (BCPP, PopART, ANRS TasP, SEARCH), HIV testing in mobile units (BCPP, ANRS TasP), and/or health campaigns (SEARCH). Finally, in some instances, trial participants are referred to government‐led health facilities to receive standard of care services that the trials do not provide (e.g. VMMC, sexually transmitted infections care, tuberculosis treatment). The models of care provide examples of how to adapt services to meet the specific needs of patients and the local capacity of the health systems.

3.4. Trial themes {#jia225048-sec-0014}
-----------------

Table [5](#jia225048-tbl-0005){ref-type="table-wrap"} outlines the main themes that are explored in the trials. The scope of the data collected underlines the trials\' potential to explore a range of issues including and beyond HIV incidence. All trials carefully monitor the uptake of trial services and the implementation of the HIV care cascade [52](#jia225048-bib-0052){ref-type="ref"}: HIV testing, linkage to care activities, treatment initiation, adherence, and/or viral suppression. Such data will help to assess the trial\'s success in reaching the UNAIDS 90‐90‐90 targets for 2020. In addition, all trials document individual health outcomes (some through accessing routine programmatic clinical data). At least a subset of trial participants is observed via repeated screening and diagnostic tests, which may occur in the clinic (BCPP, *Max*ART, PopART, ANRS TasP), at home (BCPP, PopART, ANRS TasP) or at community health campaigns and home (SEARCH). Data such as individual CD4 counts, HIV RNA metrics and results of HIV drug resistance tests, are being accumulated on more than a million people across the trials. Some studies are also using HIV viral phylogenetics to investigate transmission patterns at baseline and over time (BCPP, PopART, SEARCH and ANRS TasP). Importantly, the trials also record the costs of the interventions implemented, and will model their cost‐effectiveness, and assess their impact on the operating health systems. The collection of data on human resources, programmatic costs or length of waiting time in clinics will aid in the assessment of the feasibility of integrating universal ART in local health systems. Finally, all trials are investigating social outcomes including facilitators and barriers to accessing HIV care. Besides characterizing the trial populations with standard socio‐demographic information, these trials also collect experiences and perceptions of a sample of trial participants, community members and services providers. Such qualitative research provides evidence to understand the acceptability of the UTT strategies by the general population [29](#jia225048-bib-0029){ref-type="ref"}, [53](#jia225048-bib-0053){ref-type="ref"}, [54](#jia225048-bib-0054){ref-type="ref"}, [55](#jia225048-bib-0055){ref-type="ref"}, [56](#jia225048-bib-0056){ref-type="ref"}, [57](#jia225048-bib-0057){ref-type="ref"}, [58](#jia225048-bib-0058){ref-type="ref"}, [59](#jia225048-bib-0059){ref-type="ref"}, [60](#jia225048-bib-0060){ref-type="ref"}, [61](#jia225048-bib-0061){ref-type="ref"}, [62](#jia225048-bib-0062){ref-type="ref"}, [63](#jia225048-bib-0063){ref-type="ref"}, [64](#jia225048-bib-0064){ref-type="ref"}, [65](#jia225048-bib-0065){ref-type="ref"}, [66](#jia225048-bib-0066){ref-type="ref"}, [67](#jia225048-bib-0067){ref-type="ref"}, [68](#jia225048-bib-0068){ref-type="ref"}, [69](#jia225048-bib-0069){ref-type="ref"}. Overall, the analysis of the various themes addressed within these five trials will contribute to understanding the impact of UTT strategies in various contexts as well as inform the generalization of such a strategy to new contexts.

###### 

Themes explored in the collected trial data

                                                                                                                                                                            BCPP   *Max*ART   PopART   SEARCH                                      ANRS TasP
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------ ---------- -------- ------------------------------------------- -----------
  Implementation of the UTT care cascade                                                                                                                                                                                                           
  HIV testing                                                                                                                                                               x                 x        x                                           x
  Linkage to care                                                                                                                                                           x                 x        x                                           x
  Retention in care                                                                                                                                                         x      x          x        x                                           x
  ART initiation and adherence                                                                                                                                              x      x          x        x                                           x
  Other HIV prevention services (e.g. PrEP, MC)                                                                                                                             x                 x        x[a](#jia225048-note-0022){ref-type="fn"}   
  Community\'s health                                                                                                                                                                                                                              
  HIV disease progression (according to CD4 cell counts and/or HIV viral loads)                                                                                             x      x          x        x                                           x
  AIDS or TB or other opportunistic infections (total number of cases and incident cases)                                                                                   x      x          x        x                                           x
  Other health problems (e.g. diabetes, hypertension chronic kidney disease) (total number of cases and incident cases)[b](#jia225048-note-0023){ref-type="fn"}             x                          x[b](#jia225048-note-0023){ref-type="fn"}   x
  ART‐associated toxicity and adverse events                                                                                                                                x      x          x        x                                           x
  Mortality (overall, HIV‐related, child and/or maternal)                                                                                                                   x      x          x        x                                           x
  Mother‐to‐child HIV‐1 transmission                                                                                                                                                                   x                                           
  Community‐level HIV RNA metrics (e.g. community viral load, proportion of individuals with undetectable viral loads)                                                      x      x          x        x                                           x
  HIV drug resistance (transmitted or acquired virus mutations)                                                                                                             x      x          x        x                                           x
  HIV phylogenetics (e.g. direction of HIV‐transmission events)                                                                                                             x                 x        x                                           x
  Economic and health system impact OF UTT                                                                                                                                                                                                         
  Cost per patient per year                                                                                                                                                 x      x          x        x                                           x
  Cost‐effectiveness (e.g. modelled cost per infection averted)                                                                                                             x      x          x        x                                           x
  Heath system measures (e.g. time spent from clinic check‐in to completion of clinic visit)                                                                                       x          x        x                                           x
  Community\'s experiences                                                                                                                                                                                                                         
  Participant social and behavioural characteristics (e.g. sexual behaviour and prevention practices, quality of life, social networks, experience of HIV‐related stigma)   x      x          x        x                                           x
  Participant perceptions and attitudes towards the trial interventions (e.g. universal ART, overall care delivery, access to medical services)                             x      x                   x                                           x
  Community awareness of the trial interventions                                                                                                                                   x          x        x                                           x
  Providers attitudes towards the trial interventions                                                                                                                       x      x          x        x                                           x

UTT, universal testing and treatment; PrEP, pre‐exposure prophylaxis, MC, medical male circumcision.

Theme explored during the phase 2 of the SEARCH trial.

In the SEARCH trial, other health problems are assessed in both HIV‐ and non‐HIV‐infected individuals. In the other trials, they are only assessed in HIV‐infected individuals.

John Wiley & Sons, Ltd

3.5. Evolutions/adaptations of study design and interventions {#jia225048-sec-0015}
-------------------------------------------------------------

Over the past several years, the HIV policy landscape has been in constant evolution, prompting the on‐going trials to modify their interventions and strategies. In particular, the trials responded to the WHO recommendations related to ART initiation, preventing mother‐to‐child transmission and pre‐exposure prophylaxis (PrEP) and considered the UNAIDS 90‐90‐90 targets for 2020. In all studies, the control arms immediately followed the national guidelines. Figure [1](#jia225048-fig-0001){ref-type="fig"} shows the integration of the 2013 WHO ART recommendations in the arms of each trial, with the threshold for ART initiation changing in the control arms from ≤350 CD4 cells/μl to ≤500 CD4 cells/μl: in 2014 for Zambia (PopART), Uganda and Kenya (SEARCH), and in 2015 for South Africa (ANRS TasP, PopART) and Swaziland (*Max*ART). In 2016, the national guidelines moved to universal ART in Botswana (BCPP), Uganda (SEARCH), Kenya (SEARCH) and South Africa (PopART) and both the intervention and control trial arms switched to universal ART in all of these studies. In the same period, other parameters were altered in the trial protocols, especially to adapt to operational challenges (e.g. simplification of procedures of ART delivery, targeting of the most‐at‐risk population for HIV infection). All PopART communities in Zambia shifted to universal ART as part of a pilot for national roll‐out. SEARCH became a two‐phase trial; in the second phase, all communities were provided with universal treatment with streamlined care, and communities were re‐randomized for targeted PrEP and targeted enhanced testing and care. The BCPP trial started delivering streamlined ART initiation and follow‐up in the intervention arm (with same‐day ART initiation and fewer clinical visits for stable, virologically suppressed patients on ART). Overall, the five trials have proved to be extremely adaptive to the moving sub‐Saharan African political, economic and public health environment, preserving their ability to generate rigorous scientific evidence on UTT effectiveness.

![Evolution of the ART eligibility in the UTT trial areas from 1 January 2012 to 31 December 2016. WHO, World Health Organization; N, National recommendations; C, Control arm of the trial; I, intervention arm of the trial; A, Intervention arm A in the PopART trial; B, Intervention arm B in the PopART trial, \*shift to universal antiretroviral therapy in the PopART communities in Zambia as part of a pilot for a national roll out.](JIA2-21-e25048-g001){#jia225048-fig-0001}

4. Discussion {#jia225048-sec-0016}
=============

We present a comparative assessment of the five ongoing UTT trials in sub‐Saharan Africa. We found substantial commonalities but also differences between trials in their multidisciplinary activities. In particular, the trials\' principal aims and methodologies align in the following strategies, opportunities and goals.

4.1. The UTT trials make a plea for combination prevention {#jia225048-sec-0017}
----------------------------------------------------------

The trials deliver a wide range of biomedical, behavioural and structural interventions services to the communities. These strategies build on the plea for combination efforts for HIV prevention and care, which have progressively been gaining influence among scientists and policy makers [63](#jia225048-bib-0063){ref-type="ref"}, [70](#jia225048-bib-0070){ref-type="ref"}, [71](#jia225048-bib-0071){ref-type="ref"}, [72](#jia225048-bib-0072){ref-type="ref"}. While the UTT interventions have been designed to both lessen the burden of HIV infection and reduce vulnerability to HIV acquisition, their effect in real‐world situations remains to be proven. The ANRS TasP trial, the first UTT trial to yield final results, did not demonstrate an effect of offering immediate ART on HIV incidence [73](#jia225048-bib-0073){ref-type="ref"}, highlighting the key importance of achieving high rates of linkage to care following HIV diagnosis. The SEARCH trial, still ongoing, recently reported having nearly doubled HIV viral suppression within their study population over two years (from 44.7% to 80.2%), surpassing the UNAIDS 90‐90‐90 targets [74](#jia225048-bib-0074){ref-type="ref"}. Understanding the magnitude of the effect achieved according to the local context is precisely the aim of the trials. Our appraisal therefore emphasizes the critical monitoring of all the trial services, in order to understand gaps and support the implementation of combination interventions.

4.2. The UTT trials optimize the HIV care cascade {#jia225048-sec-0018}
-------------------------------------------------

All trials also consider the optimization of the whole HIV care cascade as key for a successful UTT strategy. Even though the overall trial attention remains on HIV incidence, key secondary outcomes related to the HIV care cascade components have progressively shown their significance when interpreting the trial impact on the HIV epidemic [3](#jia225048-bib-0003){ref-type="ref"}, [75](#jia225048-bib-0075){ref-type="ref"}, [76](#jia225048-bib-0076){ref-type="ref"}. In their initial designs, all trials underscored that UTT should aim to increase demand for HIV testing, expand HIV testing services, improve linkage to and retention in care as well as adherence to treatment [77](#jia225048-bib-0077){ref-type="ref"}, [78](#jia225048-bib-0078){ref-type="ref"}. Interestingly, this focus was subsequently formalized as the 2014 UNAIDS 90‐90‐90 targets for 2020. As a consequence, even though the trials were underway before the release of the UNAIDS targets, their results may make an important contribution in demonstrating if and how UTT can help to reach those targets and to what degree those targets might prompt a reduction of new HIV infections, in somewhat different HIV epidemic contexts.

4.3. The UTT trials represent an opportunity to design innovative models of HIV care {#jia225048-sec-0019}
------------------------------------------------------------------------------------

In the HIV/AIDS field, models of care have constantly evolved and adapted to the changing needs of communities, patients and to new scientific evidence [79](#jia225048-bib-0079){ref-type="ref"}. Recently, a flurry of new, more‐efficient HIV care models has been proposed which challenges the classic standard facility‐based model. Among them, the scale‐up of ART is leading to one of the most sweeping changes in health care delivery, especially in sub‐Saharan Africa [10](#jia225048-bib-0010){ref-type="ref"}, [80](#jia225048-bib-0080){ref-type="ref"}, [81](#jia225048-bib-0081){ref-type="ref"}. In this comparative analysis, we document the pragmatic systems and processes of UTT care models that are being field‐tested in sub‐Saharan Africa and are thus on the forefront of large‐scale practice. The trials showcase key interventions which could be integrated in the new models of care, namely community‐based approaches for HIV testing with the use of point‐of‐care HIV tests, rapid facility‐based provision of ART, community ART delivery, active follow‐up activities, integrated chronic care model with HIV and non‐communicable diseases, effective community engagement and close collaboration with the existing health services.

4.4. The UTT trials give insights on how to generalize UTT to various contexts {#jia225048-sec-0020}
------------------------------------------------------------------------------

To organize health services, including scaled‐up access to HIV care and treatment, the trials embrace HIV care approaches that are differentiated by patient type, are people‐centred and integrated across diseases and health systems functions. As the recognition of differentiated care and integrated care is growing [48](#jia225048-bib-0048){ref-type="ref"}, [49](#jia225048-bib-0049){ref-type="ref"}, [50](#jia225048-bib-0050){ref-type="ref"}, [51](#jia225048-bib-0051){ref-type="ref"}, all studies have embraced a common principle, that contextualization is imperative, with integrated services being beneficial in some settings and differentiated care being required in other settings. All trials have chosen their UTT models of care, based on the contexts in which they were implemented, including the possibility of being integrated in the local health care delivery system. Understanding and accounting for the heterogeneous social, political, economic, historical and health systems contextual factors that shape whether and how these UTT strategies work is deemed essential prior to a full‐scale rollout of a UTT strategy [59](#jia225048-bib-0059){ref-type="ref"}, [82](#jia225048-bib-0082){ref-type="ref"}. It is equally important to pay attention to the operational challenges that could result from implementing UTT, including effects of the interventions on individual\'s everyday lives, health systems and governmental structures [57](#jia225048-bib-0057){ref-type="ref"}.

4.5. The UTT trials are critical to ensure a dynamic interface between policy and research {#jia225048-sec-0021}
------------------------------------------------------------------------------------------

During their conduct, all trials have regularly exchanged information with their local and/or national health authorities, especially to communicate the trial progresses and the variety of sources of uncertainties that could influence their outputs. This review is an opportunity to provide policy makers with a comprehensive overview of the characteristics of all trials, which are likely to affect the results of the implemented UTT strategies in different contexts. All trials have efficiently adapted their design and interventions to changing guidelines both for ethical reasons and to ensure that their results are of maximal relevance to the public health landscape. Collectively, the trials represent the most relevant information to help answer policy and resource allocation questions. While the plea for UTT is now clear, many countries still need to evaluate the feasibility and cost of adopting such a strategy into their national health system [13](#jia225048-bib-0013){ref-type="ref"}. A clear understanding of the available evidence will be a key for informed policy formulation.

5. Limitations {#jia225048-sec-0022}
==============

This analysis has several limitations. First, differences in the trials\' design and data collection schemes (Table [3](#jia225048-tbl-0003){ref-type="table-wrap"}) prevented direct comparison of several indicators at baseline (Table [1](#jia225048-tbl-0001){ref-type="table-wrap"}). To improve comparison, we provided statistics from both data collected at baseline as well as national indicators (Table [S1](#jia225048-sup-0001){ref-type="supplementary-material"}).

Second, the methods applied are not based on a consensual methodology which would allow a standardized and thus validated direct comparison of the trials. Because no such methods exist yet, we developed, as a consortium, a simple way to comparatively assess all trials. The expertise and experience of the researchers was central to decide which trial components should be compared, at what level of detail, and how to interpret their differences across trials. We opted for a comprehensive description of the trials. We acknowledge that more information on the modelling, economic or social perspectives of the UTT strategies is needed to better understand the trials\' interim and final results. Such analyses will be the focus of future collaborative work within our consortium.

Third, when faced with this diversity of UTT approaches, our analysis does not answer the questions arising: are certain study designs more relevant than others? Are specific trial interventions more effective than others? With quantitative data not yet available across trials in similar situations, it is not possible to answer these questions. With this caveat in mind, we conclude that the most appropriate UTT interventions will vary by context and suspect that no single best strategy will emerge.

Finally, in this study, we focused on the five controlled trials measuring the impact of service delivery interventions for UTT in sub‐Saharan Africa. We also acknowledge that non‐randomized interventions and other operational research experiences will likely be an important source of information, particularly with regard to lessons learnt for implementation. Other novel service delivery methods for UTT are indeed piloted in observational settings but were not captured in this paper [4](#jia225048-bib-0004){ref-type="ref"}. Inclusion of non‐randomized studies and evidence may be a focus of future collaborative work.

6. Conclusion {#jia225048-sec-0023}
=============

To our knowledge, this is the first detailed exploration of the trials evaluating UTT strategies in sub‐Saharan Africa. This *a priori* exercise, i.e. before the individual study findings are released, is not usually performed by investigators. By providing detailed qualitative and quantitative insights about the different trial approaches, our analysis was intended to prospectively build the foundation for more collaborative research on UTT. It also aimed at providing valuable information as the trials are underway and starting to publish process data and findings, to guide as rapidly as possible the strengthening of services for testing and treatment in sub‐Saharan Africa, for both individual and public health benefits.

The present study reports on a wide range of attributes of the service delivery models for UTT and highlights the diversity in implementation. The population‐level impact of UTT is likely to be context‐dependent. The UT^3^C consortium, with this first paper, intends to set the path for a quicker and deeper understanding on this issue and prepare for future comparison of trial findings and to inform as efficiently as possible public policy in country and internationally.
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[^1]: The Universal Test and Treat Trial Consortium (UT^3^C) is composed of the teams of five ongoing trials: the BCPP trial (ClinicalTrials.gov NCT01965470, <https://clinicaltrials.gov/ct2/show/NCT01965470>), the *Max*ART trial (ClinicalTrials.gov NCT02909218, <https://clinicaltrials.gov/ct2/show/NCT02909218>), the HPNT071 trial (PopART trial) (ClinicalTrials.gov NCT01900977, <https://clinicaltrials.gov/ct2/show/NCT01900977>), the SEARCH trial (ClinicalTrials.gov NCT01864603, <https://clinicaltrials.gov/ct2/show/NCT01864603> ) and the ANRS 12249 TasP trial (ClinicalTrials.gov NCT01509508, <https://clinicaltrials.gov/ct2/show/NCT01509508> ).
